Norway · Delayed Price · Currency is NOK Omda AS Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw stable sales and growing recurring revenue, with EBITDA slightly down year-over-year. Guidance for 2026 is maintained, targeting NOK 500–525 million in revenue and 28–32% EBITDA margin, with strong M&A activity and AI initiatives supporting future growth.
Fiscal Year 2025
-
Record revenue and EBITDA achieved in 2025, with strong recurring revenue and improved margins. AI now central to operations, driving efficiency, and 2026 guidance targets further growth and margin expansion. Active M&A pipeline and refinancing options support future ambitions.
-
Record 30% EBITDA margin and 14% revenue growth highlight a strong quarter, with recurring revenue at 94% and robust guidance for 2025–2026. M&A remains a key growth lever, with efficiency gains and margin expansion targeted.
-
Strong Q2 results with 16% revenue growth, record recurring revenues, and EBITDA margin more than doubling year-over-year. Guidance for 2025 and 2026 is reaffirmed, with continued focus on organic and inorganic growth, cost efficiency, and prudent M&A.
-
Q1 delivered 15% revenue growth and a record NOK 93 million in recurring revenue, with EBITDA margin rising to 22%. Guidance for 2025 and 2026 remains unchanged, supported by strong recurring income and recent acquisitions.
Fiscal Year 2024
-
Record revenue and recurring income marked Q4 2024, with restructuring completed and strong cash discipline achieved. 2025 guidance targets NOK 460–485 million revenue and higher EBITDA margins, driven by organic growth and operational leverage.
-
Three acquisitions—Predicare, Averia, and Dermicus—expand the emergency and imaging software portfolio, with integration expected to be smooth and margin expansion secured through cost reductions. Cash flow and working capital improvements support continued M&A and a 30% EBITDA margin target by late 2025.
-
Q3 2024 saw NOK 103 million in income, 21% EBITDA margin, and 6% recurring revenue growth. All business areas except Emergency performed well; cost reductions and decentralization are expected to improve margins in coming quarters.
-
Organic growth reached 5.4% in Q2 2024, with recurring revenues strong and low churn. EBITDA was flat year-over-year, impacted by high personnel costs and weak professional services, but cost-saving and productivity initiatives are underway. Margin improvement and further M&A remain key priorities.